IDEXX Laboratories Inc
$ 648.73
0.34%
11 Feb - close price
- Market Cap 51,725,439,000 USD
- Current Price $ 648.73
- High / Low $ 649.74 / 636.77
- Stock P/E 49.50
- Book Value 20.09
- EPS 13.06
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.26 %
- ROE 0.66 %
- 52 Week High 769.98
- 52 Week Low 356.14
About
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Analyst Target Price
$750.23
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-02 | 2025-11-03 | 2025-08-04 | 2025-05-01 | 2025-02-03 | 2024-10-31 | 2024-08-06 | 2024-05-01 | 2024-02-05 | 2023-11-01 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 3.08 | 3.4 | 3.63 | 2.96 | 2.62 | 2.8 | 3.02 | 2.81 | 2.32 | 2.53 | 2.67 | 2.55 |
| Estimated EPS | 2.94 | 3.14 | 3.3 | 2.85 | 2.4 | 2.69 | 2.87 | 2.67 | 2.12 | 2.37 | 2.47 | 2.43 |
| Surprise | 0.14 | 0.26 | 0.33 | 0.11 | 0.22 | 0.11 | 0.15 | 0.14 | 0.2 | 0.16 | 0.2 | 0.12 |
| Surprise Percentage | 4.7619% | 8.2803% | 10% | 3.8596% | 9.1667% | 4.0892% | 5.2265% | 5.2434% | 9.434% | 6.7511% | 8.0972% | 4.9383% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 3.43 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IDXX
2026-02-11 23:56:50
IDEXX Laboratories (NASDAQ:IDXX) Executive Vice President George Fennell sold 11,345 shares of the company's stock on February 10th for over $7.3 million, reducing his ownership by 53.6%. This insider selling follows strong quarterly earnings that beat expectations, with the company reporting $3.08 EPS and $1.09 billion in revenue, and issuing positive FY 2026 EPS guidance. Analysts currently maintain a "Moderate Buy" rating for IDEXX, with an average target price of $783.33.
2026-02-11 11:56:37
Midwest Trust Co significantly increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 760.2% in Q3, purchasing 12,179 additional shares, bringing its total holdings to 13,781 shares valued at $8.81 million. This increase follows IDEXX beating Q4 earnings expectations with $3.08 EPS and $1.09 billion revenue, and their FY 2026 guidance projects EPS between $14.29 and $14.80. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $783.33.
2026-02-11 05:28:23
Artivion (AORT) is set to report its Q4 earnings this Thursday. Analysts project a 20.2% year-on-year revenue growth to $117 million and adjusted earnings of $0.18 per share. The company has a history of exceeding revenue estimates, and recent peer performance in the healthcare equipment sector offers mixed signals.
2026-02-10 19:44:13
Inogen (INGN) has seen a 10% decline in stock value over the past four weeks, reaching an oversold position according to its Relative Strength Index (RSI) of 29.69. This technical indicator, combined with rising earnings estimates from Wall Street analysts and a Zacks Rank #2 (Buy), suggests a potential trend reversal and rebound for the stock. Investors may find this an opportune time to consider entry.
2026-02-10 18:58:05
A new study by HTF MI Research evaluates the global Companion Animal Healthcare Market, projecting its size, trends, and forecast to 2033. The market, driven by rising pet ownership and humanization, includes pharmaceuticals, diagnostics, vaccines, and preventive care. Key players like Zoetis, Elanco, and Merck Animal Health are covered, with North America dominating and Asia-Pacific emerging as the fastest-growing region.
2026-02-10 09:10:32
Candriam S.C.A. significantly reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 70.9% in the third quarter, selling 56,053 shares and retaining 22,975 shares valued at approximately $14.68 million. Despite this reduction, IDEXX Laboratories reported strong quarterly earnings, beating expectations with $3.08 EPS and $1.09 billion in revenue, and provided optimistic FY2026 guidance. The stock holds a "Moderate Buy" consensus rating from analysts, with mixed price targets reflecting varying expert opinions.
